Sunday, September 7, 2025

BMO Raises Jazz Pharmaceuticals Price Target To US$205

It was announced last week wednesday that Jazz Pharmaceuticals (NASDAQ: JAZZ) would be acquiring GW Pharmaceuticals (NASDAQ: GWPH), a company discovering, developing, manufacturing and commercializing novel, regulatory approved therapeutics from its proprietary cannabinoid product, for $220 a share, a 50% premium. The total purchase price is U$7.2 billion. U$6.7 billion comes in the form of cash, while U$500 million comes in the form of Jazz Shares.

Jazz Pharmaceuticals currently has 17 analysts covering the company with a weighted 12-month price target of U$190.25. This is up from the average before the acquisition, which was U$181.67. Six analysts have strong buys while another ten have buy ratings, and one analyst has a hold rating.

Below are the recent analyst changes since the announcement.

  • Piper Sandler raises to overweight from neutral; raises target price to $175 from $150
  • RBC raises target price to $182 from $180
  • Cowen and Company raises price target to $190 from $180
  • H.C. Wainwright raises target price to $207 from $195
  • SVB Leerink raises target price to $213 from $202
  • BMO raises target price to $205 from $198

Yesterday, BMO released their note detailing their rundown of this acquisition. Gary Nachman, BMO’s analyst raised his 12-month price target to U$205 from U$198 and reiterated their outperform rating. Below you can see the key changes they have made to their 2021 estimates.

Nachman says that the deal has a “strong strategic/financial rationale by significantly accelerating diversification and growth profile,” due to GW’s flagship drug Epidiolex, and that it has potential “from the broader cannabinoid platform complementary to JAZZ’s neuroscience franchise.”

Nachman writes, “GWPH enhances diversification/growth profile at justifiable price.” As the bulk of the deal comes from new debt, Jazz believes their pro forma net leverage to go from 5.4x in the second quarter of 2021, will decline to sub 3.5x by the end of 2022. They also expect the deal to be accretive in the first full year and generate substantial free cash flow for the company. He comments, “We publish our pro forma model, raising 2021-24E revenue $537-1,410mm, EBITDA $185-790mm, and EPS $1.90-5.89 in 2022-24E ($0.25 dilution for 7-8 months in 2021).”

Nachman says that Epidiolex has great potential as its the only FDA-approved CBD medicine. He adds, “Much room remains for growth with US penetration <50% in target indications, and pursuing other refractory epilepsies could significantly expand the addressable market.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Endeavour Silver Q2 Earnings: Growth Isn’t Always Pretty

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

Aphria: Canaccord, PI Financial Reiterate Ratings And Price Targets After Q1 Financials

Yesterday, Aphria Inc (TSX: APHA) (NASDAQ: APHA) released its fiscal first quarter results. Net revenue...

Friday, October 16, 2020, 10:09:53 AM

Galaxy Digital: BMO Cuts Price Target To $16 After Crypto Crash

On Monday, Galaxy Digital Holdings Ltd. (TSX: GLXY) reported its second quarter financial results. The...

Thursday, August 11, 2022, 11:36:00 AM

Sundial: Canaccord Drops Target To $0.50 Following Q1 Results

On Monday, Sundial Growers Inc. (Nasdaq: SNDL) reported its first quarter financial results. The company...

Wednesday, May 18, 2022, 03:44:00 PM

K92: BMO Anticipates Stage 3 Expansion To Come Earlier Than Expected

On October 7th, K92 Mining Inc. (TSX: KNT) announced that the board of directors has...

Friday, October 15, 2021, 04:33:00 PM

Canaccord Raises Price Target On Teranga Gold Following Pre-Feasibility Study

Last night, Teranga Gold Corp (TSX: TGZ) announced the results of the Sabodala-Massawa Gold Complex’s...

Monday, July 27, 2020, 06:43:23 PM